The Limits of Monetary Benefit-Sharing Alone
Monetary benefit-sharing - the payment of royalties, licence fees, or revenue shares to provider country governments and communities - is the most legally specified element of ABS agreements under the Nagoya Protocol. It is also, in isolation, the least durable. A royalty payment deposited into a national fund or community account creates income; it does not, by itself, create the scientific infrastructure, trained workforce, or institutional capability that would allow Madagascar to independently characterise, protect, and commercialise its own biological heritage in the long term.
Non-monetary benefit-sharing - the transfer of knowledge, technology, training, and institutional capacity alongside monetary compensation - is explicitly recognised in the Nagoya Protocol as an integral component of ABS arrangements [1]. In practice, however, it is frequently an afterthought: mentioned in MAT negotiations, difficult to value, and rarely delivered with the rigour that monetary obligations receive. IsoGentiX's operational model is designed to make non-monetary benefit-sharing as concrete and auditable as monetary distributions.
The IsoGentiX Institute
IsoGentiX operates its laboratory programme through the IsoGentiX Institute (IGI), located in Antananarivo. The IGI functions as a genuine research facility - not a sample processing depot - with sequencing instrumentation, cryopreservation infrastructure, and bioinformatics capability. From its inception, the IGI is designed to be staffed by a majority-Malagasy workforce at all levels, including scientific and technical leadership positions, not merely field collection and sample preparation roles.
This is a deliberate structural commitment. IsoGentiX could, in principle, collect specimens in Madagascar and conduct all scientific analysis outside the country. The choice to invest in in-country infrastructure is both commercially rational - it reduces logistics costs and improves operational responsiveness - and ethically significant. It means that the scientific capability to sequence, annotate, and analyse plant genomes grows within Madagascar, in Malagasy institutions, employing Malagasy scientists.
Capacity Building in Genomics and Bioinformatics
Madagascar's university system - particularly the D-partement de Biologie et -cologie V-g-tales (DBEV) at the University of Antananarivo - has produced botanists and ecologists of genuine distinction, working under conditions of significant resource constraint. The gap between what Malagasy scientific institutions know about their own flora and what is technically possible with modern genomic tools is not primarily a function of intellectual capacity; it is a function of access to infrastructure and training.
IsoGentiX's scientific training programme is structured to close that gap. All field staff receive formal training in the Nagoya Protocol, FPIC protocols, and specimen collection standards. Laboratory staff receive hands-on training in sequencing operations. Bioinformaticians - recruited from Malagasy universities and research institutions where possible - are trained in genome assembly, annotation pipelines, and FAIR data management. Where skills do not yet exist in-country, IsoGentiX's recruitment approach prioritises developing them in-country over importing them.
Co-authorship on published datasets and scientific papers is a further non-monetary commitment. Data generated by IsoGentiX's programme, when published in open-access form as part of Earth BioGenome Project affiliation, carries the names of the Malagasy scientists and technicians who collected and processed the specimens [2]. This is not merely a formal credit - it contributes to the scientific publication records of Malagasy researchers at a time when publication record is central to career advancement and institutional funding.
Working with the Ministry of Environment
IsoGentiX's relationship with Madagascar's Ministry of Environment and Sustainable Development (MEDD) and the DGEF is conceived as a substantive partnership. The company is engaged in the process of negotiating a Framework Memorandum of Understanding with MEDD that will establish the overarching legal relationship within which individual regional PIC/MAT agreements are processed on a rolling basis.
This MoU is not merely a licence to operate - it is the instrument through which MEDD has ongoing visibility into IsoGentiX's programme, its collection regions, its scientific outputs, and its benefit-sharing distributions. IsoGentiX has committed to providing MEDD with annual reporting on collection volumes, scientific outputs, benefit-sharing distributions, and community engagement outcomes. These reports will be shared with the Ministry in full, providing the information base it needs to evaluate whether the programme is delivering on its commitments [3].
IsoGentiX has also expressed its desire to contribute positively to the development of Madagascar's ABS legislative framework, particularly during the current period of revision following the HCC constitutional ruling on the draft genetic resources law. The company does not seek a weaker regulatory framework - it seeks a framework that is clear, proportionate, and workable for compliant operators, and that protects Madagascar's sovereign rights effectively [4].
Malagasy Expertise and the Question of Control
IsoGentiX is transparent about the structure of its business: it is a commercial company, founded by and currently led by non-Malagasy founders, seeking to generate commercial returns from data derived from Madagascar's biological resources. The appropriate and responsible response to that structural reality is not to obscure it, but to be precise about where decision-making authority sits, where it is shared, and where it is reserved.
In the current phase of building the business, operational and scientific decision-making authority rests with IsoGentiX's founding team and the leadership it recruits. This is the normal structure of an early-stage commercial venture seeking to establish a track record. As the programme matures and in-country scientific capacity grows, IsoGentiX intends progressively to expand the leadership roles held by Malagasy scientists and operational professionals - not as a concession, but as a reflection of where the expertise will increasingly reside.
What IsoGentiX commits to from the outset - without qualification - is that Malagasy expertise is central to its scientific programme, not peripheral. Field collection, species identification, community engagement, laboratory processing, and bioinformatics analysis all depend on Malagasy knowledge and skills. This is not a model in which extraction happens and benefits are distributed at arm's length. It is a model in which the scientific work of characterising Madagascar's biological heritage is done, in large part, by Malagasy scientists.
The Long View
Madagascar faces an acute biological crisis. The IUCN classifies 63 per cent of the country's endemic tree species as threatened with extinction, and deforestation continues at rates that make the loss of species before they are scientifically characterised a near-certainty at current trajectories [5]. The genomic and metabolomic information contained in those species cannot be recovered once the species are gone.
IsoGentiX's collection programme is, in this sense, a time-limited operation. The window for capturing the biological intelligence of Madagascar's endemic flora - before extinction closes it - is not infinite. The urgency of that task is not an argument for cutting compliance corners; it is an argument for building the governance structures that make large-scale, systematic, compliant collection possible. That is the work IsoGentiX is engaged in, in partnership with Madagascar's government and communities [6].